Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

[1]  J. Mullol,et al.  Platelet-activating Factor Nasal Challenge Induces Nasal Congestion and Reduces Nasal Volume in Both Healthy Volunteers and Allergic Rhinitis Patients , 2013, American journal of rhinology & allergy.

[2]  R. Rosenfeld,et al.  The Value of Resident Presentations at Scientific Meetings , 2013, American journal of rhinology & allergy.

[3]  F. Simons,et al.  Histamine and H1-antihistamines: celebrating a century of progress. , 2011, The Journal of allergy and clinical immunology.

[4]  R. Maiti,et al.  Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. , 2011, Journal of drugs in dermatology : JDD.

[5]  M. Church.  Efficacy and tolerability of rupatadine at four times the recommended dose against histamine‐ and platelet‐activating factor‐induced flare responses and ex vivo platelet aggregation in healthy males , 2010, The British journal of dermatology.

[6]  R. Maiti,et al.  Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. , 2010, Archives of otolaryngology--head & neck surgery.

[7]  Y. Okayama,et al.  Activation of human mast cells through the platelet-activating factor receptor. , 2010, The Journal of allergy and clinical immunology.

[8]  D. Metcalfe,et al.  Acoustic rhinometry in the practice of allergy. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  O. Taraschenko,et al.  Actions of tacrine and galanthamine on histamine-N-methyltransferase. , 2005, Methods and findings in experimental and clinical pharmacology.

[10]  M. Andersson,et al.  Eosinophil chemotactic activity of topical PAF on the human nasal mucosa , 2004, European Journal of Clinical Pharmacology.

[11]  M. Maniscalco,et al.  The effect of platelet‐activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide , 2000, Allergy.

[12]  J. García-Rafanell,et al.  Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). , 1997, The Journal of pharmacology and experimental therapeutics.

[13]  M. Merlos,et al.  Dual effect of a new compound, rupatadine, on edema induced by platelet‐activating factor and histamine in dogs: Comparison with antihistamines and PAF antagonists , 1996 .

[14]  A. Tedeschi,et al.  Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein. , 1994, The European respiratory journal.

[15]  G. Palumbo,et al.  Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. , 1994, The Journal of allergy and clinical immunology.

[16]  A. Tedeschi,et al.  Study of the effects of paf‐acether on human nasal airways , 1991, Allergy.

[17]  A. Sala,et al.  Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways. , 1989, The American review of respiratory disease.

[18]  R. Settipane,et al.  Allergic rhinitis , 2005, Rhinology and Anterior Skull Base Surgery.